<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02311959</url>
  </required_header>
  <id_info>
    <org_study_id>14 SEIN 10</org_study_id>
    <nct_id>NCT02311959</nct_id>
  </id_info>
  <brief_title>Therapeutic Nipple Sparing Mastectomy.</brief_title>
  <acronym>MAPAM-01</acronym>
  <official_title>Therapeutic Nipple Areola Skin-sparing Mastectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, multicentric, single arm study with a sequential design using the exact&#xD;
      conditional Poisson test.&#xD;
&#xD;
      The primary objective of this prospective study is to evaluate whether selected breast&#xD;
      carcinoma patients could be treated with nipple sparing mastectomy (NSM) with an acceptable&#xD;
      low local recurrence rates.&#xD;
&#xD;
      450 patients will be included over a period of 4 years and will be followed for a 5 years&#xD;
      period (twice a year).&#xD;
&#xD;
      All patients must have a complete preoperative evaluation (bilateral mammography, bilateral&#xD;
      breast ultrasonography +/- MRI), and a histopathological diagnostic proof of carcinoma&#xD;
      (invasive or in situ, all histopathological types, first treatment or relapse).&#xD;
&#xD;
      The study procedure is represented by nipple areola skin-sparing mastectomy followed by&#xD;
      immediate breast reconstruction.&#xD;
&#xD;
      After surgery, early and late complications, including specific complications (suffering of&#xD;
      the nipple-areolar complexe and suffering of the skin flaps), will be evaluate.&#xD;
&#xD;
      An esthetic evaluation (by patient and clinician) and a quality of life evaluation will be&#xD;
      realized throughout the study.&#xD;
&#xD;
      A complementary study, prospective, non-interventional, will be proposed to patients who will&#xD;
      benefit from the same surgical technique (NSM) followed by immediate reconstruction, but in&#xD;
      the context of preventive surgery (prophylactic surgery for patients mutated or high genetic&#xD;
      risk). The aim of this complementary study, which will include a maximum of 60 patients, is&#xD;
      to evaluate associated morbidity in prophylactic NSM.&#xD;
&#xD;
      Data will be collected over a 3 months period after surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 9, 2015</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local recurrence rate.</measure>
    <time_frame>9 years.</time_frame>
    <description>Annual incidence of local recurrence defined by the number of local recurrences (skin, thoracic wall and nipple) among the patient years of follow-up..</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early and late complications</measure>
    <time_frame>9 years.</time_frame>
    <description>Early and late complications will be evaluated using NCI toxicity scale version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free Survival.</measure>
    <time_frame>9 years.</time_frame>
    <description>Disease-free survival is the period between the date of origin and date of the first event as defined below, or date of latest news (Censored Data).&#xD;
The events included in the definition of disease-free survival are local recurrence, lymph node metastases, contralateral locations, distant metastases, second breast cancer and death from any causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis Free Survival.</measure>
    <time_frame>9 years.</time_frame>
    <description>Metastasis free survival is defined as the time from inclusion until the date of metastasis recurrence or the date of the latest news (Censored data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival.</measure>
    <time_frame>9 years</time_frame>
    <description>Overall survival is defined as the time from inclusion until the date of death or the date of the latest news (Censored data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aesthetic evaluation.</measure>
    <time_frame>9 years.</time_frame>
    <description>The aesthetic evaluation will be realized by both the surgeon and the patient using to the Licket scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life.</measure>
    <time_frame>9 years.</time_frame>
    <description>The quality of life will be evaluated according to the Breast-Q questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Invasive or in situ breast carcinoma.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nipple sparing mastectomy</intervention_name>
    <description>Standardized surgical procedure by :&#xD;
Nipple sparing mastectomy with nipple core histopathology.&#xD;
Immediate breast reconstruction (flap and/or implant).&#xD;
+/- lymph node evaluation (sentinel node procedure or axillary dissection).</description>
    <arm_group_label>Invasive or in situ breast carcinoma.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with invasive breast carcinoma stage T1 or T2 and / or in situ (any&#xD;
             histological type) proved on histopathological diagnosis.&#xD;
&#xD;
          -  Patient with an indication of total mastectomy.&#xD;
&#xD;
          -  Patient without preoperative indication of adjuvant radiotherapy according to regional&#xD;
             and / or national guidelines.&#xD;
&#xD;
          -  Disease located more than 2 cm from the nipple after complete clinical and radiologic&#xD;
             breast evaluation (mammography, ultrasound +/- MRI).&#xD;
&#xD;
          -  Initial breast cancer or recurrence.&#xD;
&#xD;
          -  Patient wishing to receive immediate breast reconstruction.&#xD;
&#xD;
          -  WHO performance &lt; or = 2.&#xD;
&#xD;
          -  Patient older than 40 years.&#xD;
&#xD;
          -  For patients of childbearing age, use an effective contraceptive methods for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  For patients of childbearing potential, negative pregnancy test available before&#xD;
             inclusion.&#xD;
&#xD;
          -  Patient affiliated to a social health insurance in France.&#xD;
&#xD;
          -  Patient who signed informed consent before enrollment in the study and before any&#xD;
             specific procedure for the study.&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  Positive node on physical examination or proved by cytology.&#xD;
&#xD;
          -  Combination of 2 predictive factors of postoperative radiotherapy : macroscopic&#xD;
             multifocal, grade 2 or 3, vascular emboli, overexpressed HER2 (human epidermal growth&#xD;
             factor receptor-2), triple negative (Estrogen Receptor, Progesterone Receptor and HER2&#xD;
             negative).&#xD;
&#xD;
          -  Neoadjuvant treatment for the current disease.&#xD;
&#xD;
          -  Patient with bilateral breast cancer.&#xD;
&#xD;
          -  Paget disease.&#xD;
&#xD;
          -  T3 or T4 carcinoma.&#xD;
&#xD;
          -  Metastatic breast cancer (disease staging realized according to national or regional&#xD;
             guidelines).&#xD;
&#xD;
          -  Breast hypertrophy requiring a nipple support flap.&#xD;
&#xD;
          -  Nursing or pregnant woman.&#xD;
&#xD;
          -  Patient participating in any other interventional clinical study.&#xD;
&#xD;
          -  Any psychological, familial, geographic or social situation not to comply with medical&#xD;
             monitoring and/or procedures in the study protocol.&#xD;
&#xD;
          -  Patient protected by law.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva JOUVE, Md.</last_name>
    <role>Principal Investigator</role>
    <affiliation>IUCT-O</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de Blois</name>
      <address>
        <city>Blois</city>
        <zip>41000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pôle santé Léonard de Vinci</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Drôme Ardèche</name>
      <address>
        <city>Guilherand-Granges</city>
        <zip>07500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Mail</name>
      <address>
        <city>La Rochelle</city>
        <zip>17000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Grenoble Alpes</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Amé</name>
      <address>
        <city>Lambres-lez-Douai</city>
        <zip>59552</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Levallois-Perret</name>
      <address>
        <city>Levallois-perret</city>
        <zip>92300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Clementville</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine LACASSAGNE</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou, Assistance Publique - Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ap-Hp - Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mathilde</name>
      <address>
        <city>Rouen</city>
        <zip>76175</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital René Huguenin</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste Chirurgicale</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Etablissement Rennais du Sein - CHP St Grégoire</name>
      <address>
        <city>Saint-Grégoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSTITUT DE CANCEROLOGIE DE L'OUEST - Site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé de la Loire</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Jean</name>
      <address>
        <city>Toulouse</city>
        <zip>31077</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-Les-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast</keyword>
  <keyword>Invasive carcinoma</keyword>
  <keyword>In situ carcinoma</keyword>
  <keyword>Mastectomy</keyword>
  <keyword>Nipple areola</keyword>
  <keyword>Reconstruction</keyword>
  <keyword>Local recurrence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

